These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 20303948

  • 1. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA, Jackson MJ, Fisher R, Zoubiane G, Rose S, Jenner P.
    Eur J Pharmacol; 2010 Jun 10; 635(1-3):109-16. PubMed ID: 20303948
    [Abstract] [Full Text] [Related]

  • 2. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
    Tayarani-Binazir K, Jackson MJ, Rose S, McCreary AC, Jenner P.
    Exp Neurol; 2010 Dec 10; 226(2):320-7. PubMed ID: 20843474
    [Abstract] [Full Text] [Related]

  • 3. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P.
    Mov Disord; 2004 Jan 10; 19(1):15-21. PubMed ID: 14743355
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA, Tel BC, Jackson MJ, Hansard MJ, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, Jenner P.
    Mov Disord; 2002 Sep 10; 17(5):887-901. PubMed ID: 12360537
    [Abstract] [Full Text] [Related]

  • 13. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
    Kuoppamäki M, Al-Barghouthy G, Jackson M, Smith L, Zeng BY, Quinn N, Jenner P.
    Mov Disord; 2002 Nov 10; 17(6):1312-7. PubMed ID: 12465074
    [Abstract] [Full Text] [Related]

  • 14. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
    Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W, Jenner P.
    Mov Disord; 2005 Mar 10; 20(3):306-14. PubMed ID: 15490461
    [Abstract] [Full Text] [Related]

  • 15. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM.
    Exp Neurol; 2004 Aug 10; 188(2):471-9. PubMed ID: 15246846
    [Abstract] [Full Text] [Related]

  • 16. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
    Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P.
    J Pharmacol Exp Ther; 2006 Dec 10; 319(3):1225-34. PubMed ID: 16959959
    [Abstract] [Full Text] [Related]

  • 17. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M, Miwa H, Kondo T.
    No To Shinkei; 2002 Feb 10; 54(2):127-32. PubMed ID: 11889758
    [Abstract] [Full Text] [Related]

  • 18. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
    Katzenschlager R, Jackson MJ, Rose S, Stockwell K, Tayarani-Binazir KA, Zubair M, Smith LA, Jenner P, Lees AJ.
    Mov Disord; 2007 Apr 15; 22(5):715-9. PubMed ID: 17373723
    [Abstract] [Full Text] [Related]

  • 19. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
    Jackson MJ, Smith LA, Al-Barghouthy G, Rose S, Jenner P.
    Exp Neurol; 2007 Mar 15; 204(1):162-70. PubMed ID: 17113078
    [Abstract] [Full Text] [Related]

  • 20. A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs.
    Mihara T, Iwashita A, Matsuoka N.
    Behav Brain Res; 2008 Dec 12; 194(2):152-61. PubMed ID: 18657577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.